These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
102 related items for PubMed ID: 1940573
21. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex. Ahmad SS, Wong MY, Rawala R, Jameson BA, Walsh PN. Biochemistry; 1998 Feb 10; 37(6):1671-9. PubMed ID: 9484238 [Abstract] [Full Text] [Related]
22. Studies of factor IX concentrate therapy in hemophilia. Hultin MB. Blood; 1983 Sep 10; 62(3):677-84. PubMed ID: 6603880 [Abstract] [Full Text] [Related]
23. Half-life extension through albumin fusion technologies. Schulte S. Thromb Res; 2009 Dec 10; 124 Suppl 2():S6-8. PubMed ID: 20109653 [Abstract] [Full Text] [Related]
24. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill. Griffith MJ, Breitkreutz L, Trapp H, Briet E, Noyes CM, Lundblad RL, Roberts HR. J Clin Invest; 1985 Jan 10; 75(1):4-10. PubMed ID: 3871202 [Abstract] [Full Text] [Related]
25. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. Lenting PJ, ter Maat H, Clijsters PP, Donath MJ, van Mourik JA, Mertens K. J Biol Chem; 1995 Jun 23; 270(25):14884-90. PubMed ID: 7797466 [Abstract] [Full Text] [Related]
26. Potentially thrombogenic materials in factor IX concentrates. Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Thromb Diath Haemorrh; 1975 Jun 30; 33(3):617-31. PubMed ID: 1154317 [Abstract] [Full Text] [Related]
27. Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function. Samis JA, Kam E, Nesheim ME, Giles AR. Blood; 1998 Aug 15; 92(4):1287-96. PubMed ID: 9694717 [Abstract] [Full Text] [Related]
28. [Factor IX and factor IX inhibitor]. Higasa S. Nihon Rinsho; 2004 Dec 15; 62 Suppl 12():647-50. PubMed ID: 15658413 [No Abstract] [Full Text] [Related]
30. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G, Barrowcliffe TW. Thromb Haemost; 1995 Apr 15; 73(4):675-9. PubMed ID: 7495077 [Abstract] [Full Text] [Related]
31. [Significance of the inhibitors in disseminated intravascular coagulation syndrome and relationship among antithrombin III, platelet factor 4 and heparin (author's transl)]. Sakuragawa N, Takahashi K, Hoshiyama M, Matsuoka M. Nihon Ketsueki Gakkai Zasshi; 1977 Apr 15; 40(2):218-26. PubMed ID: 578067 [No Abstract] [Full Text] [Related]
37. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals. Smith KJ. Blood; 1988 Oct 15; 72(4):1269-77. PubMed ID: 3262386 [Abstract] [Full Text] [Related]
39. Binding of factors IX and IXa to cultured vascular endothelial cells. Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J. Proc Natl Acad Sci U S A; 1983 Jul 15; 80(13):4119-23. PubMed ID: 6602986 [Abstract] [Full Text] [Related]